Bausch Health and Salix to Present at the American Association for the Study of Liver Disease the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis Pharmaceutical Investing
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate Pharmaceutical Investing
Knight Therapeutics Announces Health Canada Approval for JORNAY PM to Treat Attention-Deficit Hyperactivity Disorder Pharmaceutical Investing
ACG Presidential Plenary to Highlight Analysis of Xifaxan Risk Reduction of Overt Hepatic Encephalopathy Recurrence Pharmaceutical Investing
